Eli Lilly launched “TuneLab,” an AI/ML platform that gives selected biotechs access to drug-discovery models trained on years of Lilly research data. Initial public partners include Circle Pharma and insitro. Lilly says the first release reflects more than $1B worth of internal data investment. Lilly says biotechs run its models locally on their own infrastructure… The post Lilly launches TuneLab, sharing AI drug-discovery models with biotechs appeared first on Drug Discovery and Develo...| Drug Discovery and Development
UTA’s Junzhou Huang secures $3.1M NIH grant to advance AI-driven antibody drug discovery, aiming to speed pandemic response and lower development costs.| Dallas Innovates
Artificial Intelligence (AI) has revolutionized drug discovery by assisting researchers with quick information searches. Sifting through vast databases, pattern recognition, virtual screening, and predictive modeling of new molecules has always been challenging. However, AI hallucinates up to 30% of the time, which is intolerable in the critical drug discovery domain.| Wisecube AI – Research Intelligence Platform
